A recent study has shown that weekly injections of semaglutide medications like Ozempic can significantly decrease the risk of severe kidney outcomes, major cardiovascular events, and death among individuals with type 2 diabetes and chronic kidney disease. Diabetes is a major risk factor for kidney disease, a leading cause of mortality in the US and globally, with about one-third of diabetes patients also having chronic kidney disease.
The study revealed that semaglutide treatment reduced the risk of severe outcomes related to diabetic kidney disease by approximately 24%. Participants receiving semaglutide experienced 331 severe events compared to 410 events in those who received a placebo, translating to 5.8 events per 100 years of follow-up for the semaglutide group versus 7.5 events for the placebo group.
High blood sugar levels in diabetes can damage kidney blood vessels, leading to strain on the heart. The research demonstrated additional benefits of semaglutide treatment, including slower kidney function decline, an 18% lower risk of major cardiovascular events, and a 20% lower risk of all-cause mortality.
The study, conducted across 28 countries with about 3,500 participants, showed consistent benefits of semaglutide across all levels of kidney function. The trial was halted early due to the highly positive results, indicating the robustness of the findings.
Experts emphasize the importance of early detection of kidney disease in diabetes patients, as the condition is often asymptomatic until advanced stages. Regular testing for kidney disease is recommended every six months using blood or urine tests.
Semaglutide's multifaceted benefits, including blood sugar reduction, weight loss, and potential heart and kidney protection, make it a promising treatment option for diabetes patients. The drug's effectiveness in addressing various complications associated with diabetes underscores its potential as a comprehensive therapeutic approach.
Despite disparities in diabetes prevalence and kidney disease among different racial groups, access to effective treatments remains a challenge. Ensuring timely and equitable access to therapies like semaglutide is crucial for improving outcomes and reducing the burden of kidney disease in high-risk populations.
